Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

被引:413
作者
van der Geest, Lydia G. M. [1 ]
Lam-Boer, Jorine't [2 ]
Koopman, Miriam [3 ]
Verhoef, Cees [4 ]
Elferink, Marloes A. G. [1 ]
de Wilt, Johannes H. W. [2 ]
机构
[1] Netherlands Comprehens Canc Org IKNL, NL-3501 DB Utrecht, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands
[3] Univ Utrecht, Dept Med Oncol, Med Ctr, Utrecht, Netherlands
[4] Rotterdam Univ, Med Ctr, Dept Surg, Rotterdam, Netherlands
关键词
Epidemiology; Colorectal cancer; Synchronous metastases; Treatment; Survival; LIVER METASTASES; LUNG METASTASES; COLON-CANCER; MANAGEMENT; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; RESECTION; OXALIPLATIN; IMPROVEMENT;
D O I
10.1007/s10585-015-9719-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to determine trends in incidence, treatment and survival of colorectal cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This nationwide population-based study included 160,278 patients diagnosed with CRC between 1996 and 2011. We evaluated changes in stage distribution, location of synchronous metastases and treatment in four consecutive periods, using Chi square tests for trend. Median survival in months was determined, using Kaplan-Meier analysis. The proportion of Stage IV CRC patients (n = 33,421) increased from 19 % (1996-1999) to 23 % (2008-2011, p < 0.001). This was predominantly due to a major increase in the incidence of lung metastases (1.7-5.0 % of all CRC patients). During the study period, the primary tumor was resected less often in Stage IV patients (65-46 %) and the use of systemic treatment has increased (29-60 %). Also an increase in metastasectomy was found in patients with one metastatic site, especially in patients with liver-only disease (5-18 %, p < 0.001). Median survival of all Stage IV CRC patients increased from 7 to 12 months. Especially in patients with metastases confined to the liver or lungs this improvement in survival was apparent (9-16 and 12-24 months respectively, both p < 0.001). In the last two decades, more lung metastases were detected and an increasing proportion of Stage IV CRC patients was treated with systemic therapy and/or metastasectomy. Survival of patients has significantly improved. However, the prognosis of Stage IV patients becomes increasingly diverse.
引用
收藏
页码:457 / 465
页数:9
相关论文
共 36 条
[11]   Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006 [J].
Elferink, M. A. G. ;
van Steenbergen, L. N. ;
Krijnen, P. ;
Lemmens, V. E. P. P. ;
Rutten, H. J. ;
Marijnen, C. A. M. ;
Nagtegaal, I. D. ;
Karim-Kos, H. E. ;
de Vries, E. ;
Siesling, S. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (08) :1421-1429
[12]  
Fritz AG., 2013, International Classification of Diseases for Oncology, V3rd ed
[13]   Risk Factors for Survival after Lung Metastasectomy in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis [J].
Gonzalez, Michel ;
Poncet, Antoine ;
Combescure, Christophe ;
Robert, John ;
Ris, Hans Beat ;
Gervaz, Pascal .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (02) :572-579
[14]   A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany [J].
Hackl, Christina ;
Gerken, Michael ;
Loss, Martin ;
Klinkhammer-Schalke, Monika ;
Piso, Pompiliu ;
Schlitt, Hans J. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (11) :1475-1481
[15]   Outcomes After Hepatic and Pulmonary Metastasectomies Compared With Pulmonary Metastasectomy Alone in Patients With Colorectal Cancer Metastasis to Liver and Lungs [J].
Hattori, Norifumi ;
Kanemitsu, Yukihide ;
Komori, Koji ;
Shimizu, Yasuhiro ;
Sano, Tsuyoshi ;
Senda, Yoshiki ;
Mitsudomi, Tetsuya ;
Fukui, Takayuki .
WORLD JOURNAL OF SURGERY, 2013, 37 (06) :1315-1321
[16]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[17]   Effect of specialist decision-making on treatment strategies for colorectal liver metastases [J].
Jones, R. P. ;
Vauthey, J-N ;
Adam, R. ;
Rees, M. ;
Berry, D. ;
Jackson, R. ;
Grimes, N. ;
Fenwick, S. W. ;
Poston, G. J. ;
Malik, H. Z. .
BRITISH JOURNAL OF SURGERY, 2012, 99 (09) :1263-1269
[18]  
Kanas Gena P, 2012, Clin Epidemiol, V4, P283, DOI 10.2147/CLEP.S34285
[19]   Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer [J].
Khattak, Muhammad A. ;
Martin, Hilary L. ;
Beeke, Carol ;
Price, Timothy ;
Carruthers, Scott ;
Kim, Susan ;
Padbury, Robert ;
Karapetis, Christos S. .
CLINICAL COLORECTAL CANCER, 2012, 11 (04) :247-254
[20]   Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial [J].
Koopman, Miriam ;
Antonini, Ninja F. ;
Douma, Joep ;
Wals, Jaap ;
Honkoop, Aafke H. ;
Erdkamp, Frans L. G. ;
de Jong, Robert S. ;
Rodenburg, Cees J. ;
Vreugdenhil, Gerard ;
Loosveld, Olaf J. L. ;
van Bochove, Aart ;
Sinnige, Harm A. M. ;
Creemers, Geert-Jan M. ;
Tesselaar, Margot E. T. ;
Slee, Peter H. Th J. ;
Werter, Marjon J. B. P. ;
Mol, Linda ;
Dalesio, Otilia ;
Punt, Cornelis J. A. .
LANCET, 2007, 370 (9582) :135-142